Chronic Idiopathic Constipation
ARDXArdelyx Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for IBSRELA/Tenapanor (NHE3 Inhibitor) in Chronic Idiopathic Constipation. The expected timing is based on the latest available company guidance and may change.
01/08/26:- Phase 3 CIC trial of IBSRELA has begun, with completion expected in H2 2027. 01/28/26:- First patient dosed in ACCEL Ph3 CIC trial; enrollment through 2026; topline data in H2 2027. 02/19/26:- ACCEL Ph3 CIC trial ongoing; enrollment completion expected end 2026; topline data in H2 2027. 04/30/26:- IBSRELA ACCEL Ph3 CIC trial ongoing; all sites initiated; enrollment completion by end 2026; topline data H2 2027. 08/06/26:- ACCEL Ph3 enrollment remains on track by end-2026; topline data expected H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.